Regeneron Pharmaceuticals is constructing an $800 million manufacturing campus in East Greenbush, N.Y. The complex is now in the third and final phase of development, which includes an $188 million, 346,000-sf production facility; a 240,000-sf lab and office building; and a six-story, 1,050-space parking garage. BBL Construction Services is managing the project with completion expected by 2022.
Fujifilm Diosynth Biotechnologies began construction in March of 2020 on a $14.5 million campus in Billingham in the United Kingdom. Designed by Ryder Architecture, the project will support the creation of innovative biologic, vaccine, and gene therapy products. Accommodating approximately 300 employees, the campus will feature a 42,000-sf office building with an inviting welcome center. Completion is expected in March of 2021. Additional R&D laboratories and manufacturing facilities will be delivered in a subsequent phase of development.
Audentes Therapeutics is planning to construct a $109 million gene therapy manufacturing facility in Sanford, N.C. The 135,000-sf project will support the production of genetic medicines based on adeno-associated virus vectors for the treatment of rare neuromuscular diseases. The center is expected to be operational by 2021. Audentes Therapeutics is a subsidiary of Astellas Pharma.
Athenex is constructing a $210 million pharmaceutical plant in Dunkirk, N.Y. Supporting the production of advanced cancer therapies, the 409,000-sf complex will provide research, office, manufacturing, and warehouse space. General contractor Exyte broke ground on the facility in May of 2018, and commercial operations will commence at the site in early 2022. The project is part of a strategic infrastructure development plan to enable Athenex to offer vertically integrated oncology services from discovery through marketing.
Merck KGaA broke ground in early 2020 on the $275 Biotech Development Center in Corsier-sur-Vevey, Switzerland. Constructed adjacent to the company's existing commercial manufacturing campus, the 169,000-sf project will provide advanced research, development, and production facilities to support the creation of innovative biological compounds for clinical studies.
Eli Lilly & Company is planning to build a $474 million pharmaceutical manufacturing center in Durham, N.C. Located in Research Triangle Park, the next-generation facility will produce injectable therapeutics and delivery devices for conditions such as Type 2 diabetes. Accommodating over 450 new employees, the project will provide integrated manufacturing, engineering, and warehouse areas. Operations will commence at the site in 2023.
HALIX opened a 72,000-sf biopharmaceutical development and manufacturing center in November of 2019 at Leiden Bio Science Park in the Netherlands. The five-story structure provides BSL-2 cleanrooms with unidirectional process flows that can easily be upgraded to BSL-3 as needed. A manufacturing line with a 250-liter bioreactor capacity supports the production of viral vaccines and viral vectors, while a separate protein manufacturing area accommodates single-use bioreactors with a capacity of up to 1,000 liters.
Thermo Fisher Scientific opened a $90 million viral vector facility in December of 2019 in Lexington, Mass. Featuring specialized GMP laboratories, the 50,000-sf project will accommodate the development, testing, and manufacture of viral vectors for the creation of gene and cell therapies. The center will act as a CDMO (contract development and manufacturing organization) site and will offer services including from drug development through clinical trials and commercial production.
WuXi Biologics is planning to expand its pharmaceutical manufacturing campus in Dundalk, Ireland. A three-story, 110,600-sf vaccine production plant will leverage single-use technologies and processes to optimize efficiency and scalability. A four-story, 62,000-sf facility housing laboratories and administrative offices will also be constructed. The project represents the second phase of development at the site, where WuXi is currently building a $365 million, 522,000-sf manufacturing center that will begin commercial operation in 2022.
Beacon Pharmaceuticals is planning to break ground by early 2020 on a 150,000-sf biosciences accelerator and headquarters facility in Jupiter, Fla. Designed by Kobi Karp Architecture & Interior Design, the $80 million facility will feature a pharmaceutical business incubator to support early-stage companies from concept to commercialization.
Pfizer is initiating a $500 million expansion of its Sanford campus with the construction of a 100,000-sf gene therapy facility. Supporting the creation of innovative treatments for genetic diseases, the project will feature advance manufacturing technologies for clinical and commercial-scale production of recombinant adeno-associated virus (rAAV) vectors. Accommodating 300 new employees, the facility will complement operations at the existing 628,000-sf Sanford complex and at the company's Chapel Hill and Kit Creek locations.
Amgen broke ground in late July of 2019 on a $200 million biomanufacturing center in West Greenwich, R.I. Featuring a highly flexible, modular design, the next-generation facility will leverage advanced technologies to reduce operational expenses, consume 80 percent less energy and water, and achieve a 75 percent decrease in carbon emissions.
HALIX is constructing a 72,000-sf cGMP facility at Leiden Bio Science Park in the Netherlands. Utilizing 1000-liter, single-use bioreactors, the five-story building will accommodate the development and manufacture of biopharmaceutical drug substances for clinical and commercial applications. Housing labs for process development, analytical development, and quality control, the structure will feature cleanrooms with unidirectional process flows with separate areas for protein manufacturing and the production of viral vaccines and viral vectors.
ADC Bio completed construction of a £5 million bioconjugation cleanroom in July of 2019. Located within the company's 70,000-sf facility in Deeside in the United Kingdom, the GMP lab will support the commercial manufacture of innovative antibody-drug conjugates for the treatment of cancer. Designed and constructed by WHP Engineering, the project houses Grade C and D cleanrooms with four-zone HVAC systems for optimal environmental containment.
ElevateBio has selected DPS Group and TRIA to design ElevateBio BaseCamp, a 108,000-sf cGMP development and manufacturing facility in Waltham. Located in a 430,000-sf office and lab building, the facility will offer integrated R&D, process development, and cGMP manufacturing services for novel therapeutic technologies.
